ifosfamide has been researched along with Recrudescence in 162 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma, in terms of objective response rate (ORR) and peripheral blood stem cell (PBSC) harvest mobilization rate." | 9.11 | ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. ( Holte, H; Jerkeman, M; Kvaløy, S; Leppä, S, 2004) |
| "Children with recurrent/refractory sarcoma were treated with ifosfamide (1,800 mg/m2/day on day 0-4), carboplatin (400 mg/m2/day on day 0-1), etoposide (100 mg/m2/day on day 0-4) and either rhG-CSF (10 microg/kg/day vs." | 9.11 | Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. ( Anderson, B; Angiolillo, A; Cairo, MS; Cheung, YK; Davenport, V; Krailo, M; Reaman, G; Van Winkle, P, 2005) |
| "In this study we explored whether a standard chemotherapy regimen consisting of mitoguazone, ifosfamide, methotrexate and etoposide (MIME) combined with 5 micrograms/kg or 10 micrograms/kg G-CSF was capable of mobilizing peripheral blood progenitor cells (PBPC) in lymphoma patients." | 9.09 | Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients. ( Aurlien, E; Holte, H; Jakobsen, E; Kvalheim, G; Kvaløy, S; Rusten, LS, 2001) |
| "One hundred and seven patients (61 with diffuse large B-cell non-Hodgkin's lymphomas and 46 with Hodgkin's disease) in relapse or following of primary therapy received ifosfamide 3 g/m2 i." | 9.09 | High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. ( Angus, B; Carey, PJ; Conn, J; Culligan, D; Haynes, A; Iqbal, A; Jackson, GH; Lennard, AL; Leonard, RC; Lucraft, H; Proctor, SJ; Russel, N; Stark, A; Taylor, PR; Wood, K, 2001) |
| "We have previously reported that combination chemotherapy based on the drugs cytarabine/platinum is effective in recurring lymphomas." | 9.08 | A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. ( Cabanillas, FC; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Swan, F; Velasquez, W, 1995) |
| "This study was designed to test if the activity of a phase II agent, ifosfamide, would have been underestimated if it was tested exclusively in a population of children and young adults with recurrent osteosarcoma." | 9.08 | Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. ( Ayala, AG; Cantor, AB; Ferguson, WS; Goorin, AM; Harris, MB; Holbrook, T; Link, MP; Shochat, SJ, 1995) |
| "This is a Phase II groupwide study of the Gynecologic Oncology Group (GOG) to determine the toxicity and efficacy of a combination of ifosfamide and doxorubicin in patients with advanced or metastatic leiomyosarcomas of the uterus who had not received other chemotherapy." | 9.08 | Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. ( Blessing, JA; Malfetano, JH; Sutton, G, 1996) |
| "Ifosfamide is an alkylating agent with proven efficacy in the treatment of solid tumours and malignant lymphomas." | 8.81 | The role of ifosfamide in the treatment of relapsed and refractory lymphoma. ( Bredenfeld, H; Diehl, V; Engert, A; Reiser, M, 2001) |
| " This report describes a young girl who developed acute pancreatitis while being treated for recurrent Wilms tumor with the ifosfamide, carboplatin, and etoposide regimen." | 7.76 | Acute pancreatitis induced by ifosfamide therapy. ( Agarwala, S; Bhatnagar, V; Garg, R, 2010) |
| "To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT)." | 7.75 | Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. ( Bacci, G; Balladelli, A; Berta, M; del Prever, AB; Fagioli, F; Ferrari, S; Palmerini, E; Picci, P; Staals, E; Vanel, D, 2009) |
| "Sixteen pediatric osteosarcoma patients, previously treated with conventional chemotherapy (including ifosfamide (IFX), 9 g/m(2)) were retreated with high-dose ifosfamide (HD-IFX, 14 g/m(2) per course), following relapse or development of a new bone tumor." | 7.73 | High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. ( Berberoğlu, S; Berrak, SG; Ilhan, IE; Jaffe, N; Pearson, M, 2005) |
| " The authors report on a 6-year-old girl with a biopsy proven pontine glioblastoma, who, after initial chemo-radiotherapy and tumor progression, experienced a prolonged second response to a salvage therapy consisting of cisplatin, etoposide, and ifosfamide." | 7.71 | Prolonged second response to cisplatin, etoposide, and ifosfamide in a child with a recurrent brainstem glioblastoma. ( Dieckmann, K; Schuller, E; Seidl, R; Slavc, I; Wandl, C, 2001) |
| "A three-drug combination of ifosfamide, epirubicin and etoposide (IEV) was used to treat 62 patients with relapsing or refractory aggressive non-Hodgkin's lymphoma (NHL; n=51) or Hodgkin's disease (HD; n=11)." | 7.71 | Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. ( Alinari, L; Baccarani, M; Bonifazi, F; Gabriele, A; Molinari, AL; Salvucci, M; Stefoni, V; Tani, M; Tura, S; Zinzani, PL; Zuffa, E, 2002) |
| "The result of a combination consisting of ifosfamide and etoposide was evaluated in 57 patients suffering from non-Hodgkin's lymphoma (NHL) who had relapsed or were resistant to adriamycin-containing combinations." | 7.67 | Ifosfamide and etoposide as salvage therapy for non-Hodgkin's lymphoma. ( Cavallin-Ståhl, E; Hagberg, H; Lind, J, 1986) |
| "Ifosfamide, an alkylating agent was used successfully in the treatment of children with steroid sensitive nephrotic syndrome with minimal changes." | 7.65 | [Ifosfamide in the treatment of nephrotic syndrome (author's transl)]. ( Daigeler, C; Gekle, D, 1977) |
| " Two toxic deaths were observed." | 6.78 | High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. ( Alexis, M; Arakelyan, N; Banos, A; Cartron, G; Courby, S; Damotte, D; Dreyfus, F; Fontan, J; Gressin, R; Gyan, E; Lamy, T; Laribi, K; Le Gouill, S; Maisonneuve, H; Quittet, P; Schmidt-Tanguy, A; Sénécal, D; Solal-Céligny, P; Tournilhac, O, 2013) |
| "Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed." | 6.73 | Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007) |
| "Ifosfamide treatment might be a feasible approach, but it necessitates hospitalization." | 6.69 | Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. ( Bamberg, M; Becker, G; Belka, C; Classen, J; Hoffmann, W; Kortmann, RD; Paulsen, F; Weinmann, M, 1999) |
| "Ifosfamide is an active agent as part of combination therapy for patients with both indolent and aggressive relapsed lymphomas, and has also been used in high-dose therapy regimens followed by stem cell or bone marrow rescue." | 6.40 | The role of ifosfamide in the treatment of lymphomas. ( Hagemeister, FB, 1999) |
| "15 months after initial treatment the first relapse of Hodgkin lymphoma was histologically confirmed and involvement of lymph nodes was identical with initial staging." | 5.35 | [Serious cutaneous toxicity following ifosfamide, gemcitabine and vinorelbine therapy in a patient with relapsed Hodgkin lymphoma and ichthyosis]. ( Konífrová, E; Móciková, H; Stríteský, J, 2009) |
| "Here we report a patient treated for Ewing sarcoma with multiple pulmonary and osseous metastases who repeatedly developed a supraventricular tachyarrhythmia following administration of ifosfamide as part of a polychemotherapy regimen." | 5.32 | Recurrent atrial ectopic tachycardia following chemotherapy with ifosfamide. ( Kramm, CM; Lawrenz, W; Müller, L; Schmidt, KG; Wessalowski, R, 2004) |
| "Standard treatment of transplant-eligible patients with relapsed diffuse large B-cell lymphoma (DLBCL) consists of rituximab and platinum-based chemotherapy, either ifosfamide, carboplatin, and etoposide (ICE) or dexamethasone, cytarabine, and cisplatin (DHAP), with autologous transplant consolidation for those with chemosensitive disease." | 5.17 | Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. ( Czuczman, MS; Edvardsen, K; Fayad, L; Fecteau, D; Fennessy, M; Henkel, K; Jewell, RC; Joyce, R; Kharfan-Dabaja, MA; Liao, Q; Lisby, S; Lossos, IS; Matasar, MJ; Moskowitz, CH; Rodriguez, MA; Shea, TC; Singh, RP; Spitzer, G, 2013) |
| "Children with recurrent/refractory sarcoma were treated with ifosfamide (1,800 mg/m2/day on day 0-4), carboplatin (400 mg/m2/day on day 0-1), etoposide (100 mg/m2/day on day 0-4) and either rhG-CSF (10 microg/kg/day vs." | 5.11 | Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. ( Anderson, B; Angiolillo, A; Cairo, MS; Cheung, YK; Davenport, V; Krailo, M; Reaman, G; Van Winkle, P, 2005) |
| "To evaluate ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma, in terms of objective response rate (ORR) and peripheral blood stem cell (PBSC) harvest mobilization rate." | 5.11 | ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. ( Holte, H; Jerkeman, M; Kvaløy, S; Leppä, S, 2004) |
| "One hundred and seven patients (61 with diffuse large B-cell non-Hodgkin's lymphomas and 46 with Hodgkin's disease) in relapse or following of primary therapy received ifosfamide 3 g/m2 i." | 5.09 | High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. ( Angus, B; Carey, PJ; Conn, J; Culligan, D; Haynes, A; Iqbal, A; Jackson, GH; Lennard, AL; Leonard, RC; Lucraft, H; Proctor, SJ; Russel, N; Stark, A; Taylor, PR; Wood, K, 2001) |
| "In this study we explored whether a standard chemotherapy regimen consisting of mitoguazone, ifosfamide, methotrexate and etoposide (MIME) combined with 5 micrograms/kg or 10 micrograms/kg G-CSF was capable of mobilizing peripheral blood progenitor cells (PBPC) in lymphoma patients." | 5.09 | Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients. ( Aurlien, E; Holte, H; Jakobsen, E; Kvalheim, G; Kvaløy, S; Rusten, LS, 2001) |
| " Relapsing progressive lymphoma patients (n = 204; non-Hodgkin's lymphoma n = 166; Hodgkin's disease n = 38) were, after induction treatment with the DHAP-VIM (cisplatin, cytarabine, dexamethasone, etoposide, ifosfamide, methotrexate) regimen, randomly (2:1) assigned to the harvest of granulocyte-macrophage colony-stimulating factor-mobilized stem cells after the second DHAP course or autologous bone marrow cells before the second DHAP course." | 5.09 | Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. ( Croockewit, AJ; Fibbe, WE; Kingma, T; Uyl-de Groot, CA; van Agthoven, M; van Imhoff, GW; van Oers, MH; Vellenga, E; Verdonck, LF; Volkers, CP; Wijermans, PJ, 2001) |
| "This is a Phase II groupwide study of the Gynecologic Oncology Group (GOG) to determine the toxicity and efficacy of a combination of ifosfamide and doxorubicin in patients with advanced or metastatic leiomyosarcomas of the uterus who had not received other chemotherapy." | 5.08 | Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. ( Blessing, JA; Malfetano, JH; Sutton, G, 1996) |
| "This study was designed to test if the activity of a phase II agent, ifosfamide, would have been underestimated if it was tested exclusively in a population of children and young adults with recurrent osteosarcoma." | 5.08 | Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. ( Ayala, AG; Cantor, AB; Ferguson, WS; Goorin, AM; Harris, MB; Holbrook, T; Link, MP; Shochat, SJ, 1995) |
| "We have previously reported that combination chemotherapy based on the drugs cytarabine/platinum is effective in recurring lymphomas." | 5.08 | A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. ( Cabanillas, FC; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Swan, F; Velasquez, W, 1995) |
| "The Intergroup Rhabdomyosarcoma Study (IRS) initiated an escalating-dose cyclophosphamide (Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine (Vcr) and actinomycin-D (Amd), known as VAC, to establish a Cyc dose with myelotoxicity comparable to an ifosfamide (Ifos), Vcr, and Amd combination regimen (VAI)." | 5.08 | Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response. ( Gehan, E; Maurer, H; Newton, WA; Ruymann, FB; Vietti, T; Wharam, M; Wiener, E, 1995) |
| "Ifosfamide is an alkylating agent with proven efficacy in the treatment of solid tumours and malignant lymphomas." | 4.81 | The role of ifosfamide in the treatment of relapsed and refractory lymphoma. ( Bredenfeld, H; Diehl, V; Engert, A; Reiser, M, 2001) |
| " The patient received ifosfamide (5 g/m2, day 1), carboplatin (300 mg/m2, day 1), etoposide (150 mg/m2, days 2-3) combined with WBH at 41." | 3.79 | [Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma]. ( Bakhshandeh, A; Bruns, I; Eberhardt, K; Wiedemann, GJ, 2000) |
| "To evaluate the prognostic value of the cell of origin (COO) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBLC), prospectively treated by rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) versus rituximab, ifosfamide, carboplatin, and etoposide and followed by intensive therapy plus autologous stem-cell transplantation on the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) trial." | 3.77 | The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. ( Boudova, L; Briere, J; Bron, D; Chevalier, C; Cogliatti, S; Cuccuini, W; Gaulard, P; Gisselbrecht, C; Hirchaud, E; Houlgatte, R; Jack, A; Mounier, N; Rosenwald, A; Schmitz, N; Soulier, J; Sundstrom, C; Thieblemont, C; Trougouboff, P; Voelker, HU; Ysebaert, L, 2011) |
| " This report describes a young girl who developed acute pancreatitis while being treated for recurrent Wilms tumor with the ifosfamide, carboplatin, and etoposide regimen." | 3.76 | Acute pancreatitis induced by ifosfamide therapy. ( Agarwala, S; Bhatnagar, V; Garg, R, 2010) |
| "To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT)." | 3.75 | Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. ( Bacci, G; Balladelli, A; Berta, M; del Prever, AB; Fagioli, F; Ferrari, S; Palmerini, E; Picci, P; Staals, E; Vanel, D, 2009) |
| " Patients who proceeded to haematopoietic stem cell transplants (HDTs) received conditioning therapy with BEAM [for the Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma (NHL) groups], or melphalan 100 mg/m2 and mitoxantrone [for the multiple myeloma (MM) patients]." | 3.73 | Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. ( Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R, 2005) |
| "The present study aimed to analyse the treatment outcome of IMVP-16/Pd (ifosfamide, methotrexate, etoposide and prednisone) followed by high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) for patients with peripheral T-cell lymphomas (PTCLs) who were previously treated with CHOP." | 3.73 | IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas. ( Im, YH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Ko, YH; Lee, J; Lee, MH; Lee, SH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS, 2005) |
| "Sixteen pediatric osteosarcoma patients, previously treated with conventional chemotherapy (including ifosfamide (IFX), 9 g/m(2)) were retreated with high-dose ifosfamide (HD-IFX, 14 g/m(2) per course), following relapse or development of a new bone tumor." | 3.73 | High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. ( Berberoğlu, S; Berrak, SG; Ilhan, IE; Jaffe, N; Pearson, M, 2005) |
| " The authors report on a 6-year-old girl with a biopsy proven pontine glioblastoma, who, after initial chemo-radiotherapy and tumor progression, experienced a prolonged second response to a salvage therapy consisting of cisplatin, etoposide, and ifosfamide." | 3.71 | Prolonged second response to cisplatin, etoposide, and ifosfamide in a child with a recurrent brainstem glioblastoma. ( Dieckmann, K; Schuller, E; Seidl, R; Slavc, I; Wandl, C, 2001) |
| "A three-drug combination of ifosfamide, epirubicin and etoposide (IEV) was used to treat 62 patients with relapsing or refractory aggressive non-Hodgkin's lymphoma (NHL; n=51) or Hodgkin's disease (HD; n=11)." | 3.71 | Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. ( Alinari, L; Baccarani, M; Bonifazi, F; Gabriele, A; Molinari, AL; Salvucci, M; Stefoni, V; Tani, M; Tura, S; Zinzani, PL; Zuffa, E, 2002) |
| " Three groups of patients were prospectively evaluated: Group I: 15 patients with Wegener's granulomatosis and 4 patients with severe scleritis received a single dose cyclophosphamide (15 mg/kg bw/day) and 250 mg prednisone i." | 3.70 | Unique alterations of thyroid function parameters after i.v. administration of alkylating drugs (cyclophosphamide and ifosfamide). ( Jockenhövel, F; Kummer, G; Mann, K; Philipp, T; Reinhardt, W; Reinwein, D; Sauter, V; Uppenkamp, M; Witzke, O, 1999) |
| "Accelerated split-course radiation with 60 to 64 Gy and concurrent chemotherapy using adriamycin/ifosfamide is a safe and effective treatment for soft tissue sarcoma." | 3.70 | [Neoadjuvant radiochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control]. ( Fietkau, R; Grabenbauer, GG; Hohenberger, W; Papadopoulos, T; Sauer, R; Schuchardt, U; Wittekind, C, 1999) |
| "The result of a combination consisting of ifosfamide and etoposide was evaluated in 57 patients suffering from non-Hodgkin's lymphoma (NHL) who had relapsed or were resistant to adriamycin-containing combinations." | 3.67 | Ifosfamide and etoposide as salvage therapy for non-Hodgkin's lymphoma. ( Cavallin-Ståhl, E; Hagberg, H; Lind, J, 1986) |
| "Ifosfamide, an alkylating agent was used successfully in the treatment of children with steroid sensitive nephrotic syndrome with minimal changes." | 3.65 | [Ifosfamide in the treatment of nephrotic syndrome (author's transl)]. ( Daigeler, C; Gekle, D, 1977) |
| "In acute lymphoblastic leukemia (ALL) the bone marrow microenvironment provides growth and survival signals that may confer resistance to chemotherapy." | 2.80 | Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. ( DiPersio, JF; Fletcher, TR; Hsu, YM; Link, DC; Schmidt, AP; Stock, W; Trinkaus, KM; Uy, GL; Westervelt, P, 2015) |
| " Two toxic deaths were observed." | 2.78 | High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. ( Alexis, M; Arakelyan, N; Banos, A; Cartron, G; Courby, S; Damotte, D; Dreyfus, F; Fontan, J; Gressin, R; Gyan, E; Lamy, T; Laribi, K; Le Gouill, S; Maisonneuve, H; Quittet, P; Schmidt-Tanguy, A; Sénécal, D; Solal-Céligny, P; Tournilhac, O, 2013) |
| "Around 20% of Hodgkin lymphoma (HL) patients are refractory to first-line therapy with ABVD (adriamycin-bleomycin-vinblastine-dacarbazine) or relapse after complete remission." | 2.76 | Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients. ( Al Nawakil, C; Beranger, N; Brice, P; Brière, J; de Bazelaire, C; de Kerviler, E; Ertault, M; Franchi, P; Sibon, D; Thieblemont, C, 2011) |
| "Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed." | 2.73 | Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007) |
| "Ifosfamide was administered by intravenous infusion over 3 h immediately followed by a 30-min infusion of topotecan." | 2.70 | Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors. ( Grübner, U; Höffken, K; Hoffmann, A; Kath, R; Merkel, U; Schneider, CP, 2002) |
| " daily for 4 days, ifosfamide 1500 mg mixed with equal dosing of mesna continuously infused i." | 2.70 | DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). ( Coleman, M; Kaufman, TP; Leonard, J; Shuster, MW, 2001) |
| "Ifosfamide treatment might be a feasible approach, but it necessitates hospitalization." | 2.69 | Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. ( Bamberg, M; Becker, G; Belka, C; Classen, J; Hoffmann, W; Kortmann, RD; Paulsen, F; Weinmann, M, 1999) |
| "Ifosfamide is an active drug in the treatment of chemotherapy-naive patients with advanced endometrial cancer and its application in currently used (combination) regimens should be considered." | 2.69 | Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group. ( Boes, GH; Cervantes, A; Hoesel, G; Pawinski, A; Pecorelli, S; Tumolo, S; van Oosterom, AT, 1999) |
| "The goal of the second German Soft Tissue Sarcoma Study CWS-86 (1985 to 1990) was to improve the prognosis in children and adolescents with soft tissue sarcoma by means of a clinical trial comprising intensive chemotherapy and risk-adapted local therapy." | 2.69 | Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. ( Gadner, H; Harms, D; Henze, G; Herbst, M; Jürgens, H; Klingebiel, T; Knietig, R; Koscielniak, E; Morgan, M; Schmidt, BF; Treuner, J, 1999) |
| "Evaluate response, duration of response, and toxicity of paclitaxel in combination with other drugs known to be effective in non-Hodgkin's lymphoma (NHL)." | 2.69 | Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. ( Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, A; Rodriguez, J; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A, 1999) |
| " Effective modulatory doses of etanidazole could not be given with acceptable toxicity using this schedule." | 2.69 | Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. ( Antman, KH; Ayash, LJ; Coleman, N; Elias, AD; Frei, E; Ibrahim, J; McCauley, M; Mills, L; Schnipper, L; Schwartz, G; Teicher, BA; Warren, D; Wheeler, C, 1998) |
| "Treatment of Hodgkin's disease (HD) and non-Hodgkin lymphomas (NHL) is still unsatisfactory in patients resistant to primary therapy or those with early relapses." | 2.69 | [Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells]. ( Adam, Z; Hájek, R; Hejlová, N; Klabusay, M; Korístek, Z; Krahulcová, E; Král, Z; Mayer, J; Müllerová, I; Navrátil, M; Penka, M; Tomíska, M; Vásová, I; Vodvárka, P; Vorlícek, J, 1998) |
| " In older patients (> 60 years) the dosage of idarubicin and ifosfamide was reduced to 75% in the initial cycle." | 2.69 | DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. ( Borchmann, P; Diehl, V; Engert, A; Münch, R; Reiser, M; Schnell, R; Straub, G; Ubelacker, R; Wilhelm, M; Wörmann, B, 1998) |
| "Relapsed or refractory Hodgkin's disease (HD) patients were treated with an intensive salvage regimen (MINE) prior to high-dose therapy (HDT) with hematopoietic stem cell support." | 2.68 | The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. ( Bastion, Y; Berger, F; Brice, P; Chéron, N; Fermé, C; Gabarre, J; Lepage, E; Morel, P; Nédellec, G; Reman, O, 1995) |
| "Therapy for group non-B patients (lymphoblastic lymphoma and pleomorphic T-cell lymphoma [PTCL]) consisted of a Berlin-Frankfurt-Münster (BFM) acute lymphoblastic leukemia protocol, including cranial irradiation for advanced stage." | 2.68 | Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. ( Gadner, H; Henze, G; Ludwig, WD; Müller-Weihrich, S; Parwaresch, R; Reiter, A; Riehm, H; Sauter, S; Schrappe, M; Sykora, KW, 1995) |
| "94 patients with refractory multiple myeloma were treated in a multicentre trial with combinations of cytotoxic drugs including anthracyclines." | 2.67 | Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish Leukaemia Group. ( Ahrenberg, P; Ala Harja, K; Almqvist, A; Elonen, E; Hallman, H; Hänninen, A; Ilvonen, M; Isomaa, B; Jouppila, J; Palva, IP, 1990) |
| "Ifosfamide is an active agent as part of combination therapy for patients with both indolent and aggressive relapsed lymphomas, and has also been used in high-dose therapy regimens followed by stem cell or bone marrow rescue." | 2.40 | The role of ifosfamide in the treatment of lymphomas. ( Hagemeister, FB, 1999) |
| "Of the classical Hodgkin lymphoma patients, the ORR were 72." | 1.56 | Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study. ( Li, J; Liu, Z; Mi, M; Wang, Y; Zhang, C; Zhang, L, 2020) |
| "The extrapolation of the Calvert formula has utility in calculating the CBDCA dosage for DeVIC ± R therapy, and therapeutic efficacy was increased by maintaining the AUC of CBDCA at ≥4." | 1.43 | Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin ( Ando, M; Ando, Y; Emi, N; Hayashi, T; Inaguma, Y; Ito, K; Okamoto, A; Okamoto, M; Tomono, A; Tsuge, M; Yamada, S, 2016) |
| "Nodal relapse is also associated with a high mortality rate." | 1.40 | Diagnosis and treatment of lymph node metastases in pediatric rhabdomyosarcoma in the Netherlands: a retrospective analysis. ( Heij, HA; Merks, JH; Spronk, P; Terwisscha van Scheltinga, CE; van Baren, R; van Noesel, MM; van Rosmalen, J; Wijnen, MH; Wijnen, RM, 2014) |
| "Eleven patients with advanced germ cell tumor refractory or relapsed after cisplatin-based chemotherapy were treated using docetaxel, ifosfamide and nedaplatin." | 1.39 | Salvage chemotherapy with docetaxel, ifosfamide and nedaplatin (DIN) for patients with advanced germ cell tumors: a preliminary report. ( Arai, Y; Ishidoya, S; Ito, A; Kaiho, Y; Mitsuzuka, K; Miyazato, M; Nakagawa, H; Namiki, S; Ohara, S; Saito, H; Yamada, S; Yamashita, S, 2013) |
| "15 months after initial treatment the first relapse of Hodgkin lymphoma was histologically confirmed and involvement of lymph nodes was identical with initial staging." | 1.35 | [Serious cutaneous toxicity following ifosfamide, gemcitabine and vinorelbine therapy in a patient with relapsed Hodgkin lymphoma and ichthyosis]. ( Konífrová, E; Móciková, H; Stríteský, J, 2009) |
| "The patient was diagnosed as having Burkitt's lymphoma (BL) with t(8;14) and t(14;18)." | 1.34 | [Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy]. ( Fujishima, M; Fujishima, N; Hirokawa, M; Inomata, M; Kameoka, Y; Saitoh, H; Saitoh, K; Sawada, K; Takahashi, N; Yamanaka, Y; Yoshioka, T, 2007) |
| "Seventeen patients had non-Hodgkin lymphoma (NHL) and 13 patients had Hodgkin disease (HD)." | 1.33 | IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. ( Abali, H; Barista, I; Demirkazik, F; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekin, F; Tekuzman, G; Turker, A; Uner, A, 2005) |
| "Here we report a patient treated for Ewing sarcoma with multiple pulmonary and osseous metastases who repeatedly developed a supraventricular tachyarrhythmia following administration of ifosfamide as part of a polychemotherapy regimen." | 1.32 | Recurrent atrial ectopic tachycardia following chemotherapy with ifosfamide. ( Kramm, CM; Lawrenz, W; Müller, L; Schmidt, KG; Wessalowski, R, 2004) |
| "First relapse was treated with high-dose BEAM chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT)." | 1.30 | Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation. ( Behringer, D; Fetscher, S; Finke, J; Kanz, L; Lange, W; Lübbert, M; Mertelsmann, R, 1997) |
| "Sites of relapse were designated as old (involved prior to HDCT) or new (previously uninvolved)." | 1.30 | High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: pattern of failure and implications for involved-field radiotherapy. ( Hallahan, D; Mundt, AJ; Williams, SF, 1997) |
| "Prospective, multicenter study in 44 soft tissue sarcoma (STS) patients with first relapse." | 1.30 | Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. ( Hess, CF; Jürgens, H; Klingebiel, T; Koscielniak, E; Pertl, U; Pötter, R; Rossi, R; Schött, C; Spaar, HJ; Treuner, J; van Heek-Romanowski, R; Willnow, U, 1998) |
| "In patients with breast cancer, especially metastatic breast cancer, undergoing HDCT and ABMT, the presence of K19 is associated with a poor prognosis." | 1.29 | Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. ( Elfenbein, GJ; Fields, KK; Janssen, WE; Moscinski, LC; Perkins, JB; Trudeau, WL, 1996) |
| " The overall response rate of 41% might be improved by increased dosage and growth factor support." | 1.29 | Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma. ( Heinz, R; Hopfinger, G; Koller, E; Pittermann, E; Schneider, B, 1995) |
| "Thirty patients with advanced squamous carcinoma of the uterine cervix recurrent after radiotherapy or surgery and refractory to first-line chemotherapeutic agents were treated with ifosfamide in a dose of 1." | 1.28 | Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study. ( Adcock, L; Blessing, JA; DeEulis, T; Sutton, GP; Webster, KD, 1989) |
| " Bone marrow suppression was the dose-limiting toxicity and led to dosage modification in 24 patients." | 1.27 | A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. ( Coleman, RE; Gallagher, C; Harper, PG; Osborne, R; Rankin, EM; Silverstone, AC; Slevin, ML; Souhami, RL; Tobias, JS; Trask, CW, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (4.94) | 18.7374 |
| 1990's | 52 (32.10) | 18.2507 |
| 2000's | 52 (32.10) | 29.6817 |
| 2010's | 44 (27.16) | 24.3611 |
| 2020's | 6 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Pavlovsky, M | 1 |
| Cubero, D | 1 |
| Agreda-Vásquez, GP | 1 |
| Enrico, A | 1 |
| Mela-Osorio, MJ | 1 |
| San Sebastián, JA | 1 |
| Fogliatto, L | 1 |
| Ovilla, R | 1 |
| Avendano, O | 1 |
| Machnicki, G | 1 |
| Barreyro, P | 1 |
| Trufelli, D | 1 |
| Villanova, P | 1 |
| Dangien, A | 1 |
| Ram-Wolff, C | 1 |
| Brice, P | 5 |
| Battistella, M | 1 |
| Roelens, M | 1 |
| Moins-Teisserenc, H | 1 |
| Peffault de Latour, R | 1 |
| Mourah, S | 1 |
| Bouaziz, JD | 1 |
| Lebbé, C | 1 |
| Bagot, M | 1 |
| de Masson, A | 1 |
| Sang, W | 1 |
| Shi, M | 1 |
| Yang, J | 1 |
| Cao, J | 1 |
| Xu, L | 1 |
| Yan, D | 1 |
| Yao, M | 1 |
| Liu, H | 1 |
| Li, W | 1 |
| Zhang, B | 1 |
| Sun, K | 1 |
| Song, X | 1 |
| Sun, C | 1 |
| Jiao, J | 1 |
| Qin, Y | 1 |
| Sang, T | 1 |
| Ma, Y | 1 |
| Wu, M | 1 |
| Gao, X | 1 |
| Cheng, H | 1 |
| Yan, Z | 1 |
| Li, D | 1 |
| Sun, H | 1 |
| Zhu, F | 1 |
| Wang, Y | 2 |
| Zeng, L | 1 |
| Li, Z | 1 |
| Zheng, J | 1 |
| Xu, K | 1 |
| Mi, M | 1 |
| Zhang, C | 1 |
| Liu, Z | 1 |
| Li, J | 1 |
| Zhang, L | 1 |
| Van de Wyngaert, Z | 1 |
| Coppo, P | 1 |
| Cervera, P | 1 |
| Fabiani, B | 1 |
| Lemonnier, MP | 1 |
| Corre, E | 1 |
| Marjanovic, Z | 1 |
| Aoudjhane, M | 1 |
| Mohty, M | 1 |
| Duléry, R | 1 |
| Wedekind, MF | 1 |
| Saraf, A | 1 |
| Willen, F | 1 |
| Audino, AN | 1 |
| Landsburg, DJ | 1 |
| Falkiewicz, MK | 1 |
| Maly, J | 1 |
| Blum, KA | 1 |
| Howlett, C | 1 |
| Feldman, T | 2 |
| Mato, AR | 2 |
| Hill, BT | 1 |
| Li, S | 1 |
| Medeiros, LJ | 1 |
| Torka, P | 1 |
| Hernandez-Ilizaliturri, F | 1 |
| Reddy, NM | 1 |
| Singavi, A | 1 |
| Fenske, TS | 1 |
| Chavez, JC | 1 |
| Kaplan, JB | 1 |
| Behdad, A | 1 |
| Petrich, AM | 1 |
| Bast, MA | 1 |
| Vose, JM | 1 |
| Olszewski, AJ | 1 |
| Costa, C | 1 |
| Lansigan, F | 1 |
| Gerson, JN | 1 |
| Barta, SK | 1 |
| Calzada, O | 1 |
| Cohen, JB | 1 |
| Lue, JK | 1 |
| Amengual, JE | 1 |
| Rivera, X | 1 |
| Persky, DO | 1 |
| Peace, DJ | 1 |
| Nathan, S | 1 |
| Cassaday, RD | 1 |
| Dholaria, B | 1 |
| Patel, RJ | 1 |
| Sluzevich, JC | 1 |
| Ailawadhi, S | 1 |
| Roy, V | 1 |
| Strati, P | 1 |
| Chihara, D | 1 |
| Oki, Y | 1 |
| Fayad, LE | 1 |
| Fowler, N | 1 |
| Nastoupil, L | 1 |
| Romaguera, JE | 5 |
| Samaniego, F | 2 |
| Garg, N | 1 |
| Feng, L | 1 |
| Wesson, ET | 1 |
| Ruben, CE | 1 |
| Stafford, MD | 1 |
| Nieto, Y | 1 |
| Khouri, IF | 1 |
| Hosing, C | 1 |
| Horowitz, SB | 1 |
| Kamble, RT | 1 |
| Fanale, MA | 1 |
| Reid, EG | 1 |
| Looney, D | 1 |
| Maldarelli, F | 1 |
| Noy, A | 5 |
| Henry, D | 1 |
| Aboulafia, D | 1 |
| Ramos, JC | 1 |
| Sparano, J | 1 |
| Ambinder, RF | 1 |
| Lee, J | 2 |
| Cesarman, E | 1 |
| Yahyaei, S | 1 |
| Mitsuyasu, R | 1 |
| Wachsman, W | 1 |
| Abuelgasim, KA | 1 |
| Alzahrani, M | 1 |
| Alsharhan, Y | 1 |
| Khairi, M | 1 |
| Hommady, M | 1 |
| Gmati, G | 1 |
| Salama, H | 1 |
| Ali, O | 1 |
| Alahmari, B | 1 |
| Masuadi, EM | 1 |
| Alaskar, A | 1 |
| Alhejazi, A | 1 |
| Damlaj, M | 1 |
| Kelly, KM | 1 |
| Cole, PD | 1 |
| Pei, Q | 1 |
| Bush, R | 1 |
| Roberts, KB | 1 |
| Hodgson, DC | 1 |
| McCarten, KM | 1 |
| Cho, SY | 1 |
| Schwartz, C | 1 |
| Rigaud, C | 1 |
| Auperin, A | 1 |
| Jourdain, A | 1 |
| Haouy, S | 1 |
| Couec, ML | 1 |
| Aladjidi, N | 1 |
| Gandemer, V | 1 |
| Lambliotte, A | 1 |
| Plat, G | 1 |
| Landman-Parker, J | 1 |
| Michon, J | 1 |
| Leblanc, T | 1 |
| Patte, C | 1 |
| Minard-Colin, V | 1 |
| Yamamoto, Y | 1 |
| Tsukiyama, I | 1 |
| Nii, S | 1 |
| Harada, R | 1 |
| Watanabe, K | 1 |
| Yabushita, H | 1 |
| Wakatsuki, A | 1 |
| Saito, H | 2 |
| Hasegawa, T | 1 |
| Yamada, S | 2 |
| Ohara, S | 1 |
| Yamashita, S | 1 |
| Mitsuzuka, K | 1 |
| Namiki, S | 1 |
| Miyazato, M | 1 |
| Kaiho, Y | 1 |
| Ito, A | 1 |
| Nakagawa, H | 1 |
| Ishidoya, S | 1 |
| Arai, Y | 1 |
| Gyan, E | 1 |
| Damotte, D | 1 |
| Courby, S | 1 |
| Sénécal, D | 1 |
| Quittet, P | 1 |
| Schmidt-Tanguy, A | 1 |
| Banos, A | 1 |
| Le Gouill, S | 1 |
| Lamy, T | 1 |
| Fontan, J | 1 |
| Maisonneuve, H | 1 |
| Alexis, M | 1 |
| Dreyfus, F | 1 |
| Tournilhac, O | 1 |
| Laribi, K | 1 |
| Solal-Céligny, P | 1 |
| Arakelyan, N | 1 |
| Cartron, G | 1 |
| Gressin, R | 1 |
| Matasar, MJ | 1 |
| Czuczman, MS | 1 |
| Rodriguez, MA | 5 |
| Fennessy, M | 1 |
| Shea, TC | 1 |
| Spitzer, G | 1 |
| Lossos, IS | 1 |
| Kharfan-Dabaja, MA | 1 |
| Joyce, R | 1 |
| Fayad, L | 2 |
| Henkel, K | 1 |
| Liao, Q | 1 |
| Edvardsen, K | 1 |
| Jewell, RC | 1 |
| Fecteau, D | 1 |
| Singh, RP | 1 |
| Lisby, S | 1 |
| Moskowitz, CH | 6 |
| Clement, J | 1 |
| Varlotto, J | 1 |
| Rybka, W | 1 |
| Frauenhoffer, E | 1 |
| Drabick, JJ | 1 |
| Kim, SK | 1 |
| Song, MK | 1 |
| Chung, JS | 1 |
| Shin, HJ | 1 |
| Terwisscha van Scheltinga, CE | 1 |
| Spronk, P | 1 |
| van Rosmalen, J | 1 |
| Wijnen, MH | 1 |
| Heij, HA | 1 |
| van Baren, R | 1 |
| Merks, JH | 1 |
| van Noesel, MM | 1 |
| Wijnen, RM | 1 |
| Chow, KF | 1 |
| Protomastro, EA | 1 |
| Yannotti, KM | 1 |
| Bhattacharyya, P | 1 |
| Yang, X | 1 |
| Donato, ML | 1 |
| Rowley, SD | 1 |
| Carini, C | 1 |
| Valentinetti, M | 1 |
| Smith, J | 1 |
| Gadaleta, G | 1 |
| Bejot, C | 1 |
| Stives, S | 1 |
| Timberg, M | 1 |
| Kdiry, S | 1 |
| Pecora, AL | 1 |
| Beaven, AW | 1 |
| Goy, A | 2 |
| Shankar, A | 1 |
| Hayward, J | 1 |
| Kirkwood, A | 1 |
| McCarthy, K | 1 |
| Hewitt, M | 1 |
| Morland, B | 1 |
| Daw, S | 1 |
| Cheah, CY | 1 |
| Herbert, KE | 1 |
| O'Rourke, K | 1 |
| Kennedy, GA | 1 |
| George, A | 1 |
| Fedele, PL | 1 |
| Gilbertson, M | 1 |
| Tan, SY | 1 |
| Ritchie, DS | 1 |
| Opat, SS | 1 |
| Prince, HM | 1 |
| Dickinson, M | 1 |
| Burbury, K | 1 |
| Wolf, M | 1 |
| Januszewicz, EH | 1 |
| Tam, CS | 1 |
| Westerman, DA | 1 |
| Carney, DA | 1 |
| Harrison, SJ | 1 |
| Seymour, JF | 1 |
| Kwong, YL | 2 |
| Moskowitz, AJ | 2 |
| Schöder, H | 1 |
| Yahalom, J | 4 |
| McCall, SJ | 1 |
| Fox, SY | 1 |
| Gerecitano, J | 1 |
| Grewal, R | 1 |
| Hamlin, PA | 2 |
| Horwitz, S | 1 |
| Kobos, R | 1 |
| Kumar, A | 1 |
| Matasar, M | 1 |
| Palomba, ML | 1 |
| Perales, MA | 1 |
| Portlock, CS | 3 |
| Sauter, C | 1 |
| Shukla, N | 1 |
| Steinherz, P | 1 |
| Straus, D | 3 |
| Trippett, T | 3 |
| Younes, A | 5 |
| Zelenetz, A | 1 |
| Esbah, O | 1 |
| Tekgündüz, E | 1 |
| Şirinoğlu Demiriz, I | 1 |
| Civriz Bozdağ, S | 1 |
| Kaya, A | 1 |
| Tetik, A | 1 |
| Kayıkçı, Ö | 1 |
| Durgun, G | 1 |
| Kocubaba, Ş | 1 |
| Altuntaş, F | 1 |
| Oh, D | 1 |
| Ahn, YC | 1 |
| Kim, SJ | 1 |
| Kim, WS | 3 |
| Ko, YH | 2 |
| Uy, GL | 1 |
| Hsu, YM | 1 |
| Schmidt, AP | 1 |
| Stock, W | 1 |
| Fletcher, TR | 1 |
| Trinkaus, KM | 1 |
| Westervelt, P | 1 |
| DiPersio, JF | 1 |
| Link, DC | 1 |
| Amorim, S | 1 |
| Fleury, I | 1 |
| Mounier, N | 4 |
| Harel, S | 1 |
| Thieblemont, C | 3 |
| Balzarotti, M | 3 |
| Brusamolino, E | 1 |
| Angelucci, E | 1 |
| Carella, AM | 1 |
| Vitolo, U | 1 |
| Russo, E | 1 |
| Congiu, A | 1 |
| Gotti, M | 1 |
| Massidda, S | 1 |
| Botto, B | 1 |
| Annechini, G | 1 |
| Spina, M | 2 |
| Re, A | 1 |
| Zilioli, VR | 1 |
| Merli, F | 1 |
| Salvi, F | 1 |
| Stelitano, C | 2 |
| Bonfichi, M | 1 |
| Rodari, M | 1 |
| Murru, R | 1 |
| Magagnoli, M | 3 |
| Anastasia, A | 1 |
| Mazza, R | 2 |
| Giordano, L | 1 |
| Santoro, A | 4 |
| Tomono, A | 1 |
| Ito, K | 1 |
| Hayashi, T | 1 |
| Ando, M | 1 |
| Ando, Y | 1 |
| Tsuge, M | 1 |
| Okamoto, A | 1 |
| Inaguma, Y | 1 |
| Okamoto, M | 2 |
| Emi, N | 1 |
| Kim, BS | 1 |
| Kim, DW | 1 |
| Im, SA | 1 |
| Kim, CW | 1 |
| Kim, TY | 1 |
| Yoon, SS | 1 |
| Heo, DS | 1 |
| Bang, YJ | 1 |
| Park, S | 1 |
| Kim, BK | 1 |
| Kim, NK | 1 |
| Griffin, TC | 1 |
| Weitzman, S | 1 |
| Weinstein, H | 1 |
| Chang, M | 1 |
| Cairo, M | 1 |
| Hutchison, R | 1 |
| Shiramizu, B | 1 |
| Wiley, J | 1 |
| Woods, D | 1 |
| Barnich, M | 1 |
| Gross, TG | 1 |
| Ferrari, S | 1 |
| del Prever, AB | 1 |
| Palmerini, E | 1 |
| Staals, E | 1 |
| Berta, M | 1 |
| Balladelli, A | 1 |
| Picci, P | 1 |
| Fagioli, F | 1 |
| Bacci, G | 1 |
| Vanel, D | 1 |
| Nishimori, H | 1 |
| Fujii, N | 1 |
| Maeda, Y | 1 |
| Matsuoka, K | 1 |
| Takenaka, K | 1 |
| Shinagawa, K | 1 |
| Ikeda, K | 1 |
| Matsuo, K | 1 |
| Harada, M | 1 |
| Tanimoto, M | 1 |
| Eckrich, MJ | 1 |
| Domm, J | 1 |
| Ho, R | 1 |
| Whitlock, JA | 1 |
| Frangoul, H | 1 |
| Fernández de Larrea, C | 1 |
| Martínez, C | 1 |
| Gaya, A | 1 |
| López-Guillermo, A | 2 |
| Rovira, M | 1 |
| Fernández-Avilés, F | 1 |
| Lozano, M | 1 |
| Bosch, F | 1 |
| Esteve, J | 1 |
| Nomdedeu, B | 1 |
| Montserrat, E | 2 |
| Carreras, E | 1 |
| Móciková, H | 1 |
| Konífrová, E | 1 |
| Stríteský, J | 1 |
| Zelenetz, AD | 3 |
| Zhang, Z | 1 |
| Filippa, D | 1 |
| Teruya-Feldstein, J | 1 |
| Kewalramani, T | 2 |
| Rice, RD | 1 |
| Maragulia, J | 1 |
| Vanak, J | 1 |
| Hamlin, P | 1 |
| Horowitz, S | 2 |
| O'Connor, OA | 1 |
| Portlock, C | 1 |
| Nimer, SD | 3 |
| Sandlund, JT | 1 |
| Pui, CH | 1 |
| Mahmoud, H | 1 |
| Zhou, Y | 1 |
| Lowe, E | 1 |
| Kaste, S | 1 |
| Kun, LE | 1 |
| Krasin, MJ | 1 |
| Onciu, M | 1 |
| Behm, FG | 1 |
| Ribeiro, RC | 1 |
| Razzouk, BI | 1 |
| Howard, SC | 1 |
| Metzger, ML | 1 |
| Hale, GA | 1 |
| Rencher, R | 1 |
| Graham, K | 1 |
| Hudson, MM | 1 |
| Gisselbrecht, C | 2 |
| Glass, B | 1 |
| Singh Gill, D | 1 |
| Linch, DC | 1 |
| Trneny, M | 1 |
| Bosly, A | 1 |
| Ketterer, N | 1 |
| Shpilberg, O | 1 |
| Hagberg, H | 3 |
| Ma, D | 1 |
| Brière, J | 3 |
| Schmitz, N | 2 |
| Garg, R | 1 |
| Agarwala, S | 1 |
| Bhatnagar, V | 1 |
| Ushijima, M | 1 |
| Yamakawa, Y | 1 |
| Sakabe, E | 1 |
| Waki, H | 1 |
| Katou, K | 1 |
| Mora, J | 1 |
| de Torres, C | 1 |
| Parareda, A | 1 |
| Torner, F | 1 |
| Galván, P | 1 |
| Rodríguez, E | 1 |
| Cardesa, T | 1 |
| Salvador, H | 1 |
| Suñol, M | 1 |
| Huguet, R | 1 |
| Cruz, O | 1 |
| Sibon, D | 1 |
| Ertault, M | 1 |
| Al Nawakil, C | 1 |
| de Bazelaire, C | 1 |
| Franchi, P | 1 |
| de Kerviler, E | 1 |
| Beranger, N | 1 |
| Fanale, M | 1 |
| Pro, B | 1 |
| Liboon, MJ | 1 |
| Nunez, C | 1 |
| Anderlini, P | 1 |
| Popat, U | 1 |
| Ji, Y | 1 |
| Kwak, LW | 1 |
| Miwa, A | 1 |
| Sekiguchi, N | 1 |
| Tanimura, A | 1 |
| Homma, C | 1 |
| Shikai, T | 1 |
| Takezako, Y | 1 |
| Yamagata, N | 1 |
| Takezako, N | 1 |
| Schäfer, N | 1 |
| Tichy, J | 1 |
| Thanendrarajan, S | 1 |
| Kim, Y | 1 |
| Stuplich, M | 1 |
| Mack, F | 1 |
| Rieger, J | 1 |
| Simon, M | 2 |
| Scheffler, B | 1 |
| Boström, J | 1 |
| Steinbach, JP | 1 |
| Herrlinger, U | 1 |
| Glas, M | 1 |
| Voelker, HU | 1 |
| Cuccuini, W | 1 |
| Hirchaud, E | 1 |
| Rosenwald, A | 1 |
| Jack, A | 1 |
| Sundstrom, C | 1 |
| Cogliatti, S | 1 |
| Trougouboff, P | 1 |
| Boudova, L | 1 |
| Ysebaert, L | 1 |
| Soulier, J | 1 |
| Chevalier, C | 1 |
| Bron, D | 1 |
| Gaulard, P | 1 |
| Houlgatte, R | 1 |
| Fox, AM | 1 |
| Dosoretz, AP | 1 |
| Mauch, PM | 1 |
| Chen, YH | 1 |
| Fisher, DC | 1 |
| LaCasce, AS | 1 |
| Freedman, AS | 1 |
| Silver, B | 1 |
| Ng, AK | 1 |
| Elstrom, RL | 1 |
| Andemariam, B | 1 |
| Martin, P | 1 |
| Ruan, J | 1 |
| Shore, TB | 1 |
| Coleman, M | 2 |
| Leonard, JP | 1 |
| Furman, RR | 1 |
| Cocorocchio, E | 1 |
| Peccatori, F | 1 |
| Vanazzi, A | 1 |
| Piperno, G | 1 |
| Calabrese, L | 1 |
| Botteri, E | 1 |
| Travaini, L | 1 |
| Preda, L | 1 |
| Martinelli, G | 1 |
| Mian, M | 1 |
| Farsad, M | 1 |
| Pescosta, N | 1 |
| Casini, M | 1 |
| Cavattoni, IM | 1 |
| Deola, S | 1 |
| Cortelazzo, S | 1 |
| Ngoma, T | 1 |
| Adde, M | 1 |
| Durosinmi, M | 1 |
| Githang'a, J | 1 |
| Aken'Ova, Y | 1 |
| Kaijage, J | 1 |
| Adeodou, O | 1 |
| Rajab, J | 1 |
| Brown, BJ | 1 |
| Leoncini, L | 1 |
| Naresh, K | 1 |
| Raphael, M | 1 |
| Hurwitz, N | 1 |
| Scanlan, P | 1 |
| Rohatiner, A | 1 |
| Venzon, D | 1 |
| Magrath, I | 2 |
| Mappa, S | 1 |
| Marturano, E | 1 |
| Licata, G | 1 |
| Frezzato, M | 1 |
| Frungillo, N | 1 |
| Ilariucci, F | 1 |
| Ferrari, A | 1 |
| Sorarù, M | 1 |
| Vianello, F | 1 |
| Baldini, L | 1 |
| Proserpio, I | 1 |
| Foppoli, M | 1 |
| Assanelli, A | 1 |
| Reni, M | 1 |
| Caligaris-Cappio, F | 1 |
| Ferreri, AJ | 1 |
| Zinzani, PL | 1 |
| Tani, M | 1 |
| Molinari, AL | 1 |
| Stefoni, V | 1 |
| Zuffa, E | 1 |
| Alinari, L | 1 |
| Gabriele, A | 1 |
| Bonifazi, F | 1 |
| Salvucci, M | 1 |
| Tura, S | 1 |
| Baccarani, M | 1 |
| Salar, A | 2 |
| Martino, R | 2 |
| Perea, G | 1 |
| Ribera, JM | 1 |
| Guardia, R | 1 |
| Escoda, L | 1 |
| Altés, A | 2 |
| Sierra, J | 2 |
| Emmanouilides, C | 1 |
| Lill, M | 1 |
| Telatar, M | 1 |
| Rosenfelt, F | 1 |
| Grody, W | 1 |
| Territo, M | 1 |
| Rosen, P | 1 |
| Qin, J | 3 |
| Satagopan, JM | 1 |
| Verbel, D | 1 |
| Straus, DJ | 1 |
| Kolb, EA | 1 |
| Kushner, BH | 1 |
| Gorlick, R | 1 |
| Laverdiere, C | 1 |
| Healey, JH | 1 |
| LaQuaglia, MP | 1 |
| Huvos, AG | 1 |
| Vu, HT | 1 |
| Wexler, L | 1 |
| Wolden, S | 1 |
| Meyers, PA | 1 |
| Müller, L | 1 |
| Kramm, CM | 1 |
| Lawrenz, W | 1 |
| Schmidt, KG | 1 |
| Wessalowski, R | 1 |
| Jerkeman, M | 1 |
| Leppä, S | 1 |
| Kvaløy, S | 2 |
| Holte, H | 2 |
| Thomson, B | 1 |
| Park, JR | 1 |
| Felgenhauer, J | 1 |
| Meshinchi, S | 1 |
| Holcenberg, J | 1 |
| Geyer, JR | 1 |
| Avramis, V | 1 |
| Douglas, JG | 1 |
| Loken, MR | 1 |
| Hawkins, DS | 1 |
| Berrak, SG | 1 |
| Pearson, M | 1 |
| Berberoğlu, S | 1 |
| Ilhan, IE | 1 |
| Jaffe, N | 1 |
| Van Winkle, P | 1 |
| Angiolillo, A | 1 |
| Krailo, M | 1 |
| Cheung, YK | 1 |
| Anderson, B | 1 |
| Davenport, V | 1 |
| Reaman, G | 1 |
| Cairo, MS | 2 |
| Abali, H | 2 |
| Oyan, B | 2 |
| Koc, Y | 2 |
| Kars, A | 2 |
| Barista, I | 1 |
| Uner, A | 1 |
| Turker, A | 2 |
| Demirkazik, F | 1 |
| Tekin, F | 1 |
| Tekuzman, G | 2 |
| Kansu, E | 2 |
| Ozdemir, E | 1 |
| Clavio, M | 1 |
| Garrone, A | 1 |
| Pierri, I | 1 |
| Michelis, GL | 1 |
| Balocco, M | 1 |
| Albarello, A | 1 |
| Varaldo, R | 1 |
| Canepa, P | 1 |
| Miglino, M | 1 |
| Ballerini, F | 1 |
| Canepa, L | 1 |
| Gobbi, M | 1 |
| Park, BB | 1 |
| Park, KW | 1 |
| Kang, JH | 1 |
| Lee, SH | 1 |
| Park, JO | 1 |
| Kim, K | 1 |
| Jung, CW | 1 |
| Park, YS | 1 |
| Im, YH | 1 |
| Kang, WK | 1 |
| Lee, MH | 1 |
| Park, K | 1 |
| Pereira, J | 1 |
| Bellesso, M | 1 |
| Pracchia, LF | 1 |
| Neto, AE | 1 |
| Beitler, B | 1 |
| de Almeida Macedo, MC | 1 |
| Dias, LC | 1 |
| Dorlhiac-Llacer, PE | 1 |
| Dulley, FL | 1 |
| Chamone, D | 1 |
| Fan, Y | 1 |
| Huang, ZY | 1 |
| Luo, LH | 1 |
| Yu, HF | 1 |
| Li, HH | 1 |
| Wu, XX | 1 |
| Wang, QS | 1 |
| Zhao, Y | 1 |
| Bo, J | 1 |
| Wang, SH | 1 |
| DA, WM | 1 |
| Yu, L | 1 |
| Castagna, L | 2 |
| Sarina, B | 2 |
| Siracusano, L | 2 |
| Nozza, A | 2 |
| Todisco, E | 1 |
| Bramanti, S | 1 |
| Russo, F | 1 |
| Timofeeva, I | 1 |
| Sugimoto, T | 1 |
| Matano, S | 2 |
| Nishijima, H | 1 |
| Kakuta, K | 1 |
| Inamura, K | 1 |
| Okamura, T | 2 |
| Munemoto, S | 1 |
| Satoh, S | 1 |
| Pinotti, G | 1 |
| Michieli, M | 1 |
| Morenghi, E | 1 |
| Tirelli, U | 1 |
| Schütt, P | 1 |
| Passon, J | 1 |
| Ebeling, P | 1 |
| Welt, A | 1 |
| Müller, S | 1 |
| Metz, K | 1 |
| Moritz, T | 1 |
| Seeber, S | 1 |
| Nowrousian, MR | 1 |
| Fujishima, N | 1 |
| Fujishima, M | 1 |
| Inomata, M | 1 |
| Yamanaka, Y | 1 |
| Saitoh, K | 1 |
| Kameoka, Y | 1 |
| Yoshioka, T | 1 |
| Saitoh, H | 1 |
| Takahashi, N | 1 |
| Hirokawa, M | 1 |
| Sawada, K | 1 |
| Vellenga, E | 2 |
| van Putten, WL | 1 |
| van 't Veer, MB | 1 |
| Zijlstra, JM | 1 |
| Fibbe, WE | 2 |
| van Oers, MH | 2 |
| Verdonck, LF | 2 |
| Wijermans, PW | 1 |
| van Imhoff, GW | 2 |
| Lugtenburg, PJ | 1 |
| Huijgens, PC | 1 |
| Yamaguchi, M | 1 |
| Suzuki, R | 1 |
| Hasegawa, Y | 1 |
| Izutsu, K | 1 |
| Suzumiya, J | 1 |
| Nakamura, S | 2 |
| Kawa, K | 1 |
| Oshimi, K | 1 |
| Urün, Y | 1 |
| Oksüzoğlu, B | 1 |
| Budakoğlu, B | 1 |
| Yildirim, N | 1 |
| Güler, T | 1 |
| Ozet, G | 1 |
| Zengin, N | 1 |
| Yap, BS | 1 |
| McCredie, KB | 1 |
| Keating, MJ | 1 |
| Bodey, GP | 2 |
| Freireich, EJ | 2 |
| Cabanillas, F | 4 |
| Hagemeister, FB | 9 |
| Dinçol, D | 1 |
| Içli, F | 1 |
| Karaoğuz, H | 1 |
| Cay, F | 1 |
| Arican, A | 1 |
| Demirkazik, A | 1 |
| Akbulut, H | 1 |
| Ruymann, FB | 1 |
| Vietti, T | 1 |
| Gehan, E | 1 |
| Wiener, E | 1 |
| Wharam, M | 1 |
| Newton, WA | 1 |
| Maurer, H | 1 |
| Hopfinger, G | 1 |
| Heinz, R | 1 |
| Koller, E | 1 |
| Schneider, B | 1 |
| Pittermann, E | 1 |
| Cabanillas, FC | 2 |
| Velasquez, W | 2 |
| McLaughlin, P | 4 |
| Swan, F | 2 |
| Kung, FH | 1 |
| Desai, SJ | 1 |
| Dickerman, JD | 1 |
| Goorin, AM | 2 |
| Harris, MB | 2 |
| Inoue, S | 1 |
| Krischer, JP | 1 |
| Murphy, SB | 1 |
| Pratt, CB | 2 |
| Toledano, S | 1 |
| Takeshima, M | 1 |
| Mochizuki, Y | 1 |
| Hattori, N | 1 |
| Kaya, H | 1 |
| Otake, S | 1 |
| Okabe, Y | 1 |
| Okumura, H | 1 |
| Yoshida, T | 1 |
| Crooks, GM | 1 |
| Sato, JK | 2 |
| Reiter, A | 2 |
| Schrappe, M | 2 |
| Parwaresch, R | 1 |
| Henze, G | 3 |
| Müller-Weihrich, S | 2 |
| Sauter, S | 1 |
| Sykora, KW | 1 |
| Ludwig, WD | 2 |
| Gadner, H | 3 |
| Riehm, H | 1 |
| Cantor, AB | 1 |
| Shochat, SJ | 1 |
| Ayala, AG | 1 |
| Ferguson, WS | 1 |
| Holbrook, T | 1 |
| Link, MP | 1 |
| Kolomiets, AG | 1 |
| Gasich, EL | 1 |
| Duboĭskaia, GP | 1 |
| Chekina, AIu | 1 |
| Moroz, AG | 1 |
| Barinskiĭ, IF | 1 |
| Votiakov, VI | 1 |
| Broun, ER | 1 |
| Belinson, JL | 1 |
| Berek, JS | 1 |
| McIntosh, D | 1 |
| Hurd, D | 1 |
| Ball, H | 1 |
| Williams, S | 1 |
| Maruyama, F | 1 |
| Tsuzuki, M | 1 |
| Nomura, T | 1 |
| Miyazaki, H | 1 |
| Wakita, M | 1 |
| Kojima, H | 1 |
| Sobue, R | 1 |
| Matsui, T | 1 |
| Ino, T | 1 |
| Prescott, RJ | 1 |
| Leonard, RC | 2 |
| Devalck, C | 1 |
| Tempels, D | 1 |
| Ferster, A | 1 |
| De Laet, MH | 1 |
| Bujan, W | 1 |
| Heiman, P | 1 |
| Sariban, E | 1 |
| Wainer, IW | 1 |
| Ducharme, J | 1 |
| Granvil, CP | 1 |
| Fermé, C | 2 |
| Bastion, Y | 1 |
| Lepage, E | 1 |
| Berger, F | 2 |
| Morel, P | 2 |
| Gabarre, J | 1 |
| Nédellec, G | 1 |
| Reman, O | 2 |
| Chéron, N | 1 |
| Lee, PK | 1 |
| Dover, JS | 1 |
| Fields, KK | 1 |
| Elfenbein, GJ | 1 |
| Trudeau, WL | 1 |
| Perkins, JB | 1 |
| Janssen, WE | 1 |
| Moscinski, LC | 1 |
| Sutton, G | 1 |
| Blessing, JA | 2 |
| Malfetano, JH | 1 |
| Edelman, DZ | 1 |
| Anteby, SO | 1 |
| Peretz, T | 1 |
| Fetscher, S | 1 |
| Lübbert, M | 1 |
| Kanz, L | 1 |
| Behringer, D | 1 |
| Finke, J | 1 |
| Mertelsmann, R | 1 |
| Lange, W | 1 |
| Miller, KD | 1 |
| Loehrer, PJ | 1 |
| Gonin, R | 1 |
| Einhorn, LH | 1 |
| Mundt, AJ | 1 |
| Williams, SF | 1 |
| Hallahan, D | 1 |
| Garay, G | 1 |
| Dupont, J | 1 |
| Dragosky, M | 1 |
| Nucifora, E | 1 |
| Cacchione, R | 1 |
| Schnidrig, P | 1 |
| Fernández, J | 1 |
| Riveros, D | 1 |
| Noviello, V | 1 |
| Bèguelin, R | 1 |
| Campestri, R | 1 |
| Albera, C | 1 |
| Nicastro, M | 1 |
| Triguboff, E | 1 |
| Pont, J | 1 |
| Höltl, W | 1 |
| Weissbach, L | 1 |
| Beyer, J | 1 |
| Siegert, W | 1 |
| Klingebiel, T | 2 |
| Pertl, U | 1 |
| Hess, CF | 1 |
| Jürgens, H | 2 |
| Koscielniak, E | 2 |
| Pötter, R | 1 |
| van Heek-Romanowski, R | 1 |
| Rossi, R | 1 |
| Schött, C | 1 |
| Spaar, HJ | 1 |
| Willnow, U | 1 |
| Treuner, J | 2 |
| Kirch, C | 1 |
| Gachot, B | 1 |
| Germann, N | 1 |
| Blot, F | 1 |
| Nitenberg, G | 1 |
| Elias, AD | 1 |
| Wheeler, C | 1 |
| Ayash, LJ | 1 |
| Schwartz, G | 1 |
| Ibrahim, J | 1 |
| Mills, L | 1 |
| McCauley, M | 1 |
| Coleman, N | 1 |
| Warren, D | 1 |
| Schnipper, L | 1 |
| Antman, KH | 1 |
| Teicher, BA | 1 |
| Frei, E | 1 |
| Ribrag, V | 1 |
| Nasr, F | 1 |
| Bouhris, JH | 1 |
| Bosq, J | 1 |
| Brault, P | 1 |
| Girinsky, T | 1 |
| Cosset, JM | 1 |
| Munck, JN | 1 |
| Corti, C | 1 |
| Decaudin, D | 1 |
| Pico, JL | 1 |
| Hayat, M | 1 |
| Carde, P | 1 |
| Mayer, J | 1 |
| Korístek, Z | 1 |
| Vásová, I | 1 |
| Müllerová, I | 1 |
| Král, Z | 1 |
| Navrátil, M | 1 |
| Klabusay, M | 1 |
| Vorlícek, J | 1 |
| Vodvárka, P | 1 |
| Hejlová, N | 1 |
| Penka, M | 1 |
| Krahulcová, E | 1 |
| Tomíska, M | 1 |
| Adam, Z | 1 |
| Hájek, R | 1 |
| Bonfante, V | 2 |
| Viviani, S | 2 |
| Devizzi, L | 2 |
| Di Russo, A | 2 |
| Zanini, M | 1 |
| Soncini, F | 1 |
| Soto Parra, H | 1 |
| Valagussa, P | 2 |
| Bonadonna, G | 2 |
| Reiser, M | 2 |
| Schnell, R | 1 |
| Straub, G | 1 |
| Borchmann, P | 1 |
| Wilhelm, M | 1 |
| Ubelacker, R | 1 |
| Wörmann, B | 1 |
| Münch, R | 1 |
| Diehl, V | 3 |
| Engert, A | 2 |
| Plantier-Colcher, I | 1 |
| Dupriez, B | 1 |
| Detourmignies, L | 1 |
| Jouet, JP | 1 |
| Fenaux, P | 1 |
| Bauters, F | 1 |
| Bachier, C | 1 |
| Preti, H | 1 |
| Sarris, AH | 2 |
| Weber, D | 1 |
| Michelagnoli, MP | 1 |
| Lewis, IJ | 1 |
| Gattamaneni, HR | 1 |
| Bailey, CC | 1 |
| Lashford, LS | 1 |
| Reinhardt, W | 1 |
| Sauter, V | 1 |
| Jockenhövel, F | 1 |
| Kummer, G | 1 |
| Uppenkamp, M | 1 |
| Witzke, O | 1 |
| Philipp, T | 1 |
| Reinwein, D | 1 |
| Mann, K | 1 |
| Sauer, R | 1 |
| Schuchardt, U | 1 |
| Hohenberger, W | 1 |
| Wittekind, C | 1 |
| Papadopoulos, T | 1 |
| Grabenbauer, GG | 1 |
| Fietkau, R | 1 |
| Paulsen, F | 1 |
| Hoffmann, W | 1 |
| Becker, G | 1 |
| Belka, C | 1 |
| Weinmann, M | 1 |
| Classen, J | 1 |
| Kortmann, RD | 1 |
| Bamberg, M | 1 |
| Pawinski, A | 1 |
| Tumolo, S | 1 |
| Hoesel, G | 1 |
| Cervantes, A | 1 |
| van Oosterom, AT | 1 |
| Boes, GH | 1 |
| Pecorelli, S | 1 |
| van de Velde, H | 1 |
| Bosquée, L | 1 |
| Weynants, P | 1 |
| Canon, JL | 1 |
| Rosier, JF | 1 |
| Humblet, Y | 1 |
| Harms, D | 1 |
| Herbst, M | 1 |
| Schmidt, BF | 1 |
| Morgan, M | 1 |
| Knietig, R | 1 |
| Rodriguez, J | 1 |
| Preti, A | 1 |
| Sureda, A | 1 |
| Brunet, S | 1 |
| Bakhshandeh, A | 1 |
| Bruns, I | 1 |
| Eberhardt, K | 1 |
| Wiedemann, GJ | 1 |
| Fujita, A | 1 |
| Takabatake, H | 1 |
| Tagaki, S | 1 |
| Sekine, K | 1 |
| Kosmas, C | 1 |
| Tsavaris, NB | 1 |
| Malamos, NA | 1 |
| Vadiaka, M | 1 |
| Koufos, C | 1 |
| Hedrick, EE | 1 |
| Filippa, DA | 1 |
| Louie, D | 1 |
| Gonzales, M | 1 |
| Walits, J | 1 |
| Coady-Lyons, N | 1 |
| Frank, R | 1 |
| Bertino, JR | 1 |
| O'Brien, JP | 1 |
| Shen, V | 1 |
| Krailo, MD | 1 |
| Bauer, M | 1 |
| Miser, JS | 1 |
| Blatt, J | 1 |
| Blazar, BR | 1 |
| Frierdich, S | 1 |
| Liu-Mares, W | 1 |
| Reaman, GH | 1 |
| van Besien, K | 1 |
| Rodriguez, A | 1 |
| Tomany, S | 1 |
| Donato, M | 1 |
| Sarris, A | 1 |
| Giralt, S | 1 |
| Mehra, R | 1 |
| Andersson, B | 1 |
| Gajewski, J | 1 |
| Champlin, R | 1 |
| Mullier, J | 1 |
| Beauvois, S | 1 |
| Gebhart, M | 1 |
| Roelandts, M | 1 |
| Van Houtte, P | 1 |
| Maubec, E | 1 |
| Oberlin, O | 2 |
| Belhadj, K | 1 |
| Roujeau, JC | 1 |
| Schuller, E | 1 |
| Seidl, R | 1 |
| Wandl, C | 1 |
| Dieckmann, K | 1 |
| Slavc, I | 1 |
| Aurlien, E | 1 |
| Jakobsen, E | 1 |
| Rusten, LS | 1 |
| Kvalheim, G | 1 |
| Proctor, SJ | 1 |
| Taylor, PR | 1 |
| Angus, B | 1 |
| Wood, K | 1 |
| Lennard, AL | 1 |
| Lucraft, H | 1 |
| Carey, PJ | 1 |
| Stark, A | 1 |
| Iqbal, A | 1 |
| Haynes, A | 1 |
| Russel, N | 1 |
| Culligan, D | 1 |
| Conn, J | 1 |
| Jackson, GH | 1 |
| Bredenfeld, H | 1 |
| Leonard, J | 1 |
| Shuster, MW | 1 |
| Kaufman, TP | 1 |
| Di Nicola, M | 1 |
| Magni, M | 1 |
| Matteucci, P | 1 |
| Grisanti, S | 1 |
| Gianni, AM | 1 |
| van Agthoven, M | 1 |
| Croockewit, AJ | 1 |
| Wijermans, PJ | 1 |
| Volkers, CP | 1 |
| Kingma, T | 1 |
| Uyl-de Groot, CA | 1 |
| Diviné, M | 1 |
| Stamatoullas, A | 1 |
| Voillat, L | 1 |
| Jaubert, J | 1 |
| Lederlin, P | 1 |
| Colin, P | 1 |
| Salles, G | 1 |
| Naresh, KN | 1 |
| Banavali, SD | 1 |
| Bhatia, KG | 1 |
| Soman, CS | 1 |
| Advani, SH | 1 |
| Schneider, CP | 1 |
| Merkel, U | 1 |
| Grübner, U | 1 |
| Kath, R | 1 |
| Höffken, K | 1 |
| Hoffmann, A | 1 |
| Gekle, D | 1 |
| Daigeler, C | 1 |
| Lampert, F | 1 |
| Harbott, J | 1 |
| Niemeyer, CM | 1 |
| Ritter, J | 1 |
| Habrand, JL | 1 |
| Zucker, JM | 1 |
| Brunat-Mentigny, M | 1 |
| Terrier-Lacombe, MJ | 1 |
| Dubousset, J | 1 |
| Gentet, JC | 1 |
| Schmitt, C | 1 |
| Ponvert, D | 1 |
| Carrié, C | 1 |
| Harstrick, A | 1 |
| Schmoll, HJ | 1 |
| Wilke, H | 1 |
| Köhne-Wömpner, CH | 1 |
| Stahl, M | 1 |
| Schöber, C | 1 |
| Casper, J | 1 |
| Bruderek, L | 1 |
| Schmoll, E | 1 |
| Bokemeyer, C | 1 |
| Palva, IP | 1 |
| Ahrenberg, P | 1 |
| Ala Harja, K | 1 |
| Almqvist, A | 1 |
| Elonen, E | 1 |
| Hallman, H | 1 |
| Hänninen, A | 1 |
| Ilvonen, M | 1 |
| Isomaa, B | 1 |
| Jouppila, J | 1 |
| Meier, W | 1 |
| Eiermann, W | 1 |
| Stieber, P | 1 |
| Fateh-Moghadam, A | 1 |
| Schneider, A | 1 |
| Hepp, H | 1 |
| Enblad, G | 1 |
| Glimelius, B | 1 |
| Lindemalm, C | 1 |
| Sutton, GP | 1 |
| Adcock, L | 1 |
| Webster, KD | 1 |
| DeEulis, T | 1 |
| Sampi, K | 1 |
| Masaoka, T | 1 |
| Takagi, T | 1 |
| Sakamoto, S | 1 |
| Mikuni, C | 1 |
| Kano, Y | 1 |
| Coleman, RE | 1 |
| Harper, PG | 1 |
| Gallagher, C | 1 |
| Osborne, R | 1 |
| Rankin, EM | 1 |
| Silverstone, AC | 1 |
| Slevin, ML | 1 |
| Souhami, RL | 1 |
| Tobias, JS | 1 |
| Trask, CW | 1 |
| Gasser, AB | 1 |
| Steward, WP | 1 |
| Wagstaff, J | 1 |
| Scarffe, JH | 1 |
| Crowther, D | 1 |
| Cavallin-Ståhl, E | 1 |
| Lind, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequential Infusion of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor(CAR) T Cells Against Relapsed and Refractory B-cell Lymphoma[NCT03207178] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | ||
| Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma[NCT01590732] | Phase 1 | 22 participants (Actual) | Interventional | 2012-10-29 | Completed | ||
| Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma[NCT00598169] | Phase 1 | 23 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| A Single Arm, Safety and Efficacy Study of Ofatumumab in Combination With ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive Lymphoma Prior to Autologous Stem Cell Transplantation[NCT00823719] | Phase 2 | 61 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone (R2-GOD) in Treatment of Relapse/Refractory DLBCL:A Phase I Study[NCT03795571] | Phase 1 | 12 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | ||
| National, Open-label, Multicentre Phase I-II Study of Combination R-ESHAP With Lenalidomide as Salvage Therapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Candidates to Stem-cell Transplantation[NCT02340936] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma[NCT01508312] | Phase 2 | 46 participants (Anticipated) | Interventional | 2012-01-05 | Active, not recruiting | ||
| Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia[NCT01429610] | Phase 2 | 78 participants (Actual) | Interventional | 2011-11-30 | Active, not recruiting | ||
| Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence[NCT02681302] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2016-06-07 | Active, not recruiting | ||
| Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab[NCT00137995] | Phase 3 | 481 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma： a Single-arm, Single-centre, Open-label Trial[NCT05786989] | Phase 4 | 32 participants (Anticipated) | Interventional | 2023-02-28 | Recruiting | ||
| An Open-Label, Pilot Study To Investigate Feasibility and Safety Of Using Bortezomib, Rituximab, Ifosfamide, Carboplatin, Etoposide As Salvage Regime In Previously Treated Patients With Diffuse Large B-Cell Lymphoma[NCT01226849] | Phase 1 | 6 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma[NCT01466868] | Phase 2 | 22 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions) | ||
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| IGEV +/- Bortezomib (Velcade) as Induction Before High Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma After First Line Treatment: a Randomized Phase II Trial. On Behalf of Intergruppo Italiano Linfomi[NCT00636311] | Phase 2 | 13 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Randomised Phase III Study On The Effect Of The Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) During Sequential Chemotherapy Followed By Autologous Stem Cell Transplantation In Patients With Relapse B-Cell Non-Hodgkin Lymphoma(HOVON 44 STUDY)[NCT00012051] | Phase 3 | 340 participants (Anticipated) | Interventional | 2000-09-30 | Completed | ||
| Phase I Trial of High-dose Topotecan in Association With Carboplatin, With Peripheral Blood Stem Cell Support in Patients With First Relapsed Ovarian Carcinoma Without Platinum-treatment Since 6-12 Months[NCT01177501] | Phase 1 | 3 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to choice of the principal investigator) | ||
| Open-labeled, Multicenter, Phase I/II Study of Imatinib Combined With ESHAP as Salvage Therapy in Relapsed/Refractory Non-Hodgkin's Lymphoma[NCT02431403] | Phase 1/Phase 2 | 94 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| Phase I/II Trial of Yttrium-90-labeled Daclizumab (Anti-CD25) Radioimmunotherapy With High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin's Lymphoma[NCT01468311] | Phase 1/Phase 2 | 6 participants (Actual) | Interventional | 2011-10-11 | Terminated (stopped due to Poor enrollment and ability to radioconjugate Daclizumab. Neither Center for Cancer Research (CCR) or Nuclear Medicine/Radiology wanted to do the facilities upgrade and hire personnel needed to radioconjugate the drug at the Clinical Center.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CL is the clearance of drug from plasma, which is defined as the volume of plasma from which drug is removed per unit time. (NCT00823719)
Timeframe: Study Day 1 up to Study Day 85 (up to 12 weeks)
| Intervention | mL/hr (Geometric Mean) |
|---|---|
| Ofatumumab + DHAP | 8.7 |
| Ofatumumab + ICE | 9.2 |
| Total Ofatumumab + Chemotherapy | 9.0 |
CR is defined as the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms. (NCT00823719)
Timeframe: From Day 14 (Study Day 56) to Day 21 (approximately Study Day 63) of treatment Cycle 3, or earlier in the case of early withdrawal or missing response assessment for Cycle 3
| Intervention | participants (Number) |
|---|---|
| Ofatumumab + DHAP | 11 |
| Ofatumumab + ICE | 11 |
| Total Ofatumumab + Chemotherapy | 22 |
Responders with OR included participants with complete response (CR) and partial response (PR). This was based on adequate responses from the investigator assessment after the completion of treatment. CR: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms. PR: at least a 50% decrease from baseline in the sum of the product of the diameters of target lesions. (NCT00823719)
Timeframe: From Day 14 (Study Day 56) to Day 21 (approximately Study Day 63) of treatment Cycle 3, or earlier in the case of early withdrawal or missing response assessment for Cycle 3
| Intervention | participants (Number) |
|---|---|
| Ofatumumab + DHAP | 18 |
| Ofatumumab + ICE | 18 |
| Total Ofatumumab + Chemotherapy | 36 |
CD34+ cells are a mixture of stem cells and white blood cells of various degrees of maturity. Stem cell mobilization is the process of stimulating the hematopoietic stem cells (CD34+) to move out of the bone marrow and into the bloodstream, where they can be collected via a process called apheresis. Successful mobilization was defined as the collection of >2x10^6 CD34+ cells/kg. Only those participants, who commenced mobilization, following the administration of ofatumumab in combination with either ICE or DHAP combination chemotherapy, were assessed. (NCT00823719)
Timeframe: During treatment Cycle 2 (Study Days 22-42) and/or Cycle 3 (Study Days 43-63)
| Intervention | participants (Number) |
|---|---|
| Ofatumumab + DHAP | 23 |
| Ofatumumab + ICE | 20 |
| Total Ofatumumab + Chemotherapy | 43 |
Overall survival is defined as the interval of time between the date of treatment start and the date of death due to any cause. For participants who did not die, time of death was censored at the date of last contact. (NCT00823719)
Timeframe: From Day 14 (Study Day 56) to Day 21 (approximately Study Day 63) of treatment Cycle 3, or earlier in the case of early withdrawal or missing response assessment for Cycle 3
| Intervention | days (Median) |
|---|---|
| Ofatumumab + DHAP | 433.0 |
| Ofatumumab + ICE | NA |
| Total Ofatumumab + Chemotherapy | 508.0 |
PFS is defined as the interval of time between the date of treatment start and the earlier of the date of disease progression and the date of death due to any cause. Disease progression was based on the assessments locally by investigators for the disease under study. Disease progression was based on imaging data or clinical assessment data (if radiologic assessment data were not possible or assessment was not performed). (NCT00823719)
Timeframe: From Day 14 (Study Day 56) to Day 21 (approximately Study Day 63) of treatment Cycle 3, or earlier in the case of early withdrawal or missing response assessment for Cycle 3
| Intervention | days (Median) |
|---|---|
| Ofatumumab + DHAP | 301.0 |
| Ofatumumab + ICE | 288.0 |
| Total Ofatumumab + Chemotherapy | 288.0 |
t1/2 is defined as terminal phase half-life, which is the time required for the amount of the drug in the body to decrease by half. (NCT00823719)
Timeframe: Study Day 1 up to Study Day 85 (up to 12 weeks)
| Intervention | hr (Geometric Mean) |
|---|---|
| Ofatumumab + DHAP | 595 |
| Ofatumumab + ICE | 646 |
| Total Ofatumumab + Chemotherapy | 624 |
Vss is the apparent volume of distribution when plasma concentrations are measured under steady state conditions. At steady state, the plasma concentration-time profile of the drug is similar after each dose. (NCT00823719)
Timeframe: Study Day 1 up to Study Day 85 (up to 12 weeks)
| Intervention | Liters (Geometric Mean) |
|---|---|
| Ofatumumab + DHAP | 7.12 |
| Ofatumumab + ICE | 8.13 |
| Total Ofatumumab + Chemotherapy | 7.68 |
AUC(0-tau) is the area under the plasma concentration-time curve from time zero (0) over the dosing interval, tau, and is a measure of drug exposure. Tau is 21 days (504 hours) in this study. (NCT00823719)
Timeframe: Cycle 3 (Study Day 43; 3 weeks)
| Intervention | µg*hr/mL (Geometric Mean) | ||
|---|---|---|---|
| Cycle 3, 300 mg; n=4, 6, 10 | Cycle 3, 1000 mg; n=14, 13, 30 | Cycle 3 both doses; n=18, 19, 40 | |
| Ofatumumab + DHAP | 95112 | 112676 | 108511 |
| Ofatumumab + ICE | 83385 | 95341 | 91391 |
| Total Ofatumumab + Chemotherapy | 87891 | 101948 | 98236 |
AUC is defined as the area under the ofatumumab (Ofa) concentration-time curve as a measure of drug exposure. AUC(0-inf) is AUC from the start of infusion extrapolated to infinite time. Results are reported by first dose group and combined, as appropriate. (NCT00823719)
Timeframe: Cycle 1 Day 1 (Study Day 1; up to 1 week) and Cycle 3 (Study Day 43; up to 6 weeks)
| Intervention | µg*hr/mL (Geometric Mean) | ||||
|---|---|---|---|---|---|
| Cycle 1 Day 1, 300 mg; n=4, 17, 21 | Cycle 1 Day 1, 1000 mg; n=22, 18, 40 | Cycle 3, 300 mg; n=4, 6, 10 | Cycle 3, 1000 mg; n=14, 13, 30 | Cycle 3, both doses; n=18, 19, 40 | |
| Ofatumumab + DHAP | 34056 | 115741 | 222713 | 258487 | 250070 |
| Ofatumumab + ICE | 33606 | 105898 | 206389 | 216885 | 213514 |
| Total Ofatumumab + Chemotherapy | 33691 | 111203 | 212770 | 232310 | 227263 |
Cmax is defined as the maximum concentration of drug in plasma samples for the dosing occasion. (NCT00823719)
Timeframe: Cycle 1 Day 1 (Study Day 1; up to 48 hours), Cycle 1 Day 8 (Study Day 8; up to 24 hours), Cycle 3 (Study Day 43; up to 48 hours)
| Intervention | µg/mL (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1, 300 mg; n=4, 17, 21 | Cycle 1 Day 1, 1000 mg; n=22, 18, 40 | Cycle 1 Day 8, 300 mg; n=4, 13, 17 | Cycle 1 Day 8, 1000 mg; n=21, 18, 39 | Cycle 3, 300 mg; n=4, 11, 15 | Cycle 3, 1000 mg; n=14, 14, 33 | Cycle 3, both doses; n=18, 25, 48 | |
| Ofatumumab + DHAP | 89.8 | 323 | 245 | 431 | 416 | 466 | 455 |
| Ofatumumab + ICE | 80.0 | 268 | 273 | 368 | 417 | 397 | 406 |
| Total Ofatumumab + Chemotherapy | 81.8 | 297 | 266 | 401 | 417 | 421 | 420 |
Human anti-human antibodies (HAHA) indicate immune response to the administered human monoclonal antibody in a two-step assay. A positive screening result is confirmed in a second step. Negative Conclusive is subset of Negative and is a negative HAHA test result with an ofatumumab concentration <200 µg/mL in a pharmacokinetic sample collected at the same time as the HAHA sample. Data are presented when a HAHA sample was collected. WD, withdrawal; FU, follow up. (NCT00823719)
Timeframe: Study Day 1 up to approximately Study Day 63
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Positive at Day 1; n=26, 35, 61 | Negative at Day 1; n=26, 35, 61 | Positive at Early WD or FU; n=24, 30, 54 | Negative at Early WD or FU; n=24, 30, 54 | Negative conclusive at Early WD or FU; n=24, 30, 5 | |
| Ofatumumab + DHAP | 0 | 26 | 0 | 24 | 18 |
| Ofatumumab + ICE | 0 | 35 | 0 | 30 | 28 |
| Total Ofatumumab + Chemotherapy | 0 | 61 | 0 | 54 | 46 |
Neutropenia is defined as an abnormal decrease in the number of neutrophils (type of white blood cell in blood) in the blood. Febrile neutropenia is the development of fever in participants with neutropenia. Pancytopenia is defined as inadequate blood-cell formation by bone marrow, resulting in a lack of all blood-cell types. (NCT00823719)
Timeframe: Study Day 1 to approximately Study Day 63
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any Event of Decreased Neutrophils; n=26, 35, 61 | Neutropenia; n=12, 11, 23 | Febrile Neutropenia; n=12, 11, 23 | Pancytopenia; n=12, 11, 23 | |
| Ofatumumab + DHAP | 12 | 7 | 8 | 1 |
| Ofatumumab + ICE | 11 | 11 | 1 | 0 |
| Total Ofatumumab + Chemotherapy | 23 | 18 | 9 | 1 |
Anaemia is defined as a pathological deficiency in the oxygen-carrying component of the blood, measured in unit volume concentrations of hemoglobin, red blood-cell volume, or red blood-cell number. Pancytopenia is defined as inadequate blood-cell formation by bone marrow, resulting in a lack of all blood-cell types. (NCT00823719)
Timeframe: Study Day 1 to approximately Study Day 63
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any Event of Decreased Hemoglobin; n=26, 35, 61 | Anaemia; n=16, 18, 34 | Haemoglobin Decreased; n=16, 18, 34 | Pancytopenia; n=16, 18, 34 | |
| Ofatumumab + DHAP | 16 | 14 | 3 | 1 |
| Ofatumumab + ICE | 18 | 16 | 2 | 0 |
| Total Ofatumumab + Chemotherapy | 34 | 30 | 5 | 1 |
Thrombocytopenia is defined as an abnormal decrease in the number of platelets in circulatory blood. Pancytopenia is defined as inadequate blood-cell formation by bone marrow, resulting in a lack of all blood-cell types. (NCT00823719)
Timeframe: Study Day 1 to approximately Study Day 63
| Intervention | participants (Number) | ||
|---|---|---|---|
| Any Event of Decreased Platelets; n=26, 35, 61 | Thrombocytopenia; n=21, 19, 40 | Pancytopenia; n=21, 19, 40 | |
| Ofatumumab + DHAP | 21 | 20 | 1 |
| Ofatumumab + ICE | 19 | 19 | 0 |
| Total Ofatumumab + Chemotherapy | 40 | 39 | 1 |
Ctrough is defined as the trough plasma concentration, which is the measured concentration at the end of a dosing interval (taken directly before the start of the next infusion). (NCT00823719)
Timeframe: Cycle 1 Day 8 (Study Day 8; up to 8 hours prior to infusion start), Cycle 2 (Study Day 22; up to 7 hours prior to infusion start), Cycle 3 (Study Day 43; up to 6 hours prior to infusion start)
| Intervention | µg/mL (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 8, 300 mg; n=4, 15, 19 | Cycle 1 Day 8, 1000 mg; n=19, 18, 37 | Cycle 2, 300 mg; n=4, 16, 20 | Cycle 2, 1000 mg; n=21, 18, 39 | Cycle 3, 300 mg; n=4, 13, 17 | Cycle 3, 1000 mg; n=18, 18, 40 | Cycle 3, both doses; n=22, 31, 57 | |
| Ofatumumab + DHAP | 31.8 | 95.8 | 112 | 138 | 120 | 153 | 146 |
| Ofatumumab + ICE | 28.3 | 106 | 71.5 | 147 | 76.7 | 122 | 100 |
| Total Ofatumumab + Chemotherapy | 29.1 | 101 | 78.2 | 142 | 85.2 | 134 | 117 |
Complete response rate is defined as the time it takes a participant to achieve a complete response. Response is assessed by the Revised Response Criteria for Malignant Lymphoma. Complete response requires all of the following: complete disappearance of all detectable clinical evidence of disease and disease related symptoms if present before therapy. A post treatment residual mass is permitted as long as it is positron emission tomography (PET) negative. If a pretreatment PET scan was negative, all lymph nodes and nodal masses must have regressed on computed tomography (CT) to normal size (<1.5 cm in their greatest transverse diameter for nodes >1.5 cm before therapy); Previously involved nodes that were 1.1 to 1.5 cm in their long axis and more than 1.0 cm in their short axis before treatment must have decreased to <1.0 cm in their short axis after treatment. (NCT01468311)
Timeframe: 20 months post autologous stem cell transplant
| Intervention | months (Median) |
|---|---|
| Yttrium-90-labeled Daclizumab + Chemotherapy | 7.5 |
DFS is defined as the amount of time participants remain disease free. (NCT01468311)
Timeframe: DFS is evaluated at day 100 post autologous stem cell transplant, then 1-4 times yearly for 5 years
| Intervention | months (Median) |
|---|---|
| Yttrium-90-labeled Daclizumab + Chemotherapy | 36 |
Patients who develop either a Common Terminology Criteria in Adverse Events (CTCAE) v4.0 grade 3 or greater non-hematologic toxicity, with the exception of fatigue, of more than 5 days duration possibly, probably or definitely related to the infusion of 90Y-daclizumab prior to the start of Carmustine, Etoposide, Cytarabine, [Ara-C, Cytosine Arabinoside] and Melphalan (BEAM) chemotherapy (Day - 6) will have developed by definition a dose-limiting toxicity (DLT). (NCT01468311)
Timeframe: 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Yttrium-90-labeled Daclizumab + Chemotherapy | 0 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01468311)
Timeframe: 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Yttrium-90-labeled Daclizumab + Chemotherapy | 3 |
Overall survival is defined as the time from the date of registration to the date of death due to any cause or if no death occurs to the last documented information on the patient. (NCT01468311)
Timeframe: OS is evaluated at day 100 post autologous stem cell transplant, then 1-4 times yearly for 5 years
| Intervention | months (Median) |
|---|---|
| Yttrium-90-labeled Daclizumab + Chemotherapy | 36 |
7 reviews available for ifosfamide and Recrudescence
| Article | Year |
|---|---|
Durable Response in Relapsed Adolescent Peripheral T-cell Lymphoma: A Case Report and Review of the Literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carboplatin; Etoposide; Huma | 2022 |
[Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer].
Topics: Altretamine; Antineoplastic Agents; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Ovarian Neopla | 1996 |
The role of ifosfamide in the treatment of lymphomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Ste | 1999 |
[Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2000 |
The role of ifosfamide in the treatment of relapsed and refractory lymphoma.
Topics: Antineoplastic Agents, Alkylating; Disease-Free Survival; Humans; Ifosfamide; Lymphoma; Recurrence; | 2001 |
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2002 |
Ifosfamide studies for primary or recurrent pediatric malignant solid tumors and leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Ifosfamide; Leukemia; Lymphoma; Neopl | 1990 |
75 trials available for ifosfamide and Recrudescence
| Article | Year |
|---|---|
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Topics: Adult; Aged; Anemia; Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; CD4-CD8 R | 2020 |
A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Resistance; Etoposide; Humans; Ifo | 2018 |
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; APOBEC-3G Deaminase; Bortezomib; Carbop | 2018 |
Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Deoxycytidin | 2019 |
Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Cycl | 2019 |
Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carbopl | 2019 |
High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2013 |
Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; | 2013 |
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Brentuximab Ved | 2014 |
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carbop | 2015 |
Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Cell Activating Factor; Bone Marrow; | 2015 |
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality The | 2016 |
Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Su | 2009 |
A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2009 |
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Epidemiologic | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2010 |
Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2011 |
Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Dis | 2011 |
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disea | 2011 |
Ranimustine, ifosfamide, procarbazine, dexamethasone, and etoposide therapy for central nervous system recurrence of diffuse large B-cell lymphoma in patients with poor performance status: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2011 |
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease.
Topics: Adolescent; Adult; Africa South of the Sahara; Antineoplastic Combined Chemotherapy Protocols; Burki | 2012 |
Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigen | 2002 |
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic | 2003 |
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2003 |
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Pr | 2004 |
Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacteremia; Bone | 2004 |
Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 2005 |
Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; | 2005 |
Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brazil; Cytarabine; Developing Co | 2006 |
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fe | 2007 |
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Thera | 2007 |
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Dexamethasone | 2008 |
Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Dact | 1995 |
Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 1995 |
[MMIP chemotherapy for the treatment of the relapsed and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifos | 1995 |
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 1995 |
Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Child; Clinical Trials, Phase II as Topic; Female; Humans; Ifosfamide; Male; Neop | 1995 |
Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: a Gynecologic Oncology Group pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com | 1994 |
Pilot study and randomised trial of mitozantrone and ifosfamide for relapsed non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma group (SNLG) Working Party on Therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Lymphoma, N | 1993 |
The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Th | 1995 |
A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; | 1995 |
Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1996 |
Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Idarubicin; | 1997 |
Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Hypoxia; Disease-Free Survi | 1998 |
VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; | 1998 |
[Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etopos | 1998 |
Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Hodgkin Disease; Humans; Ifosfamide; | 1998 |
DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dexamethas | 1998 |
The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytara | 1999 |
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabin | 1998 |
Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazin | 1999 |
Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Cyclophosphamide; Endometrial Neopla | 1999 |
Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic tumor control and high central nervous system relapse rate. Groupe d'Oncologie-Pneumologie Clini
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined M | 1999 |
Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 1999 |
Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; | 1999 |
[Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2000 |
Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Ci | 2000 |
Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell | 2001 |
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cisplatin; Cyc | 2001 |
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 2001 |
Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Follow-Up S | 2001 |
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component R | 2001 |
High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Ho | 2001 |
DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Re | 2001 |
High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cystitis; Female; Granulocyte Colony-Stimulat | 2001 |
Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chi- | 2001 |
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dis | 2002 |
Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2002 |
Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish Leukaemia Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Doxorubicin | 1990 |
[Aclarubicin-combined combination chemotherapy in patients with refractory or relapsed non-Hodgkin's lymphoma].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Drug Resi | 1989 |
Treatment of relapsed non-Hodgkin's lymphoma with a combination of hydroxyurea, ifosfamide, and etoposide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; E | 1985 |
81 other studies available for ifosfamide and Recrudescence
| Article | Year |
|---|---|
Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Etoposid | 2022 |
Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin | 2020 |
Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deo | 2020 |
Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carboplatin; Drug | 2021 |
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2017 |
Relapsed subcutaneous panniculitis-like T cell lymphoma: role of haploidentical hematopoietic stem cell transplant.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclo | 2017 |
[A case of Ifosfamide-induced dysuria which could be avoided by changing the regimen of mesna].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dysuria; Female; Humans; Ifosfamid | 2013 |
Salvage chemotherapy with docetaxel, ifosfamide and nedaplatin (DIN) for patients with advanced germ cell tumors: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule | 2013 |
Unusual case of recurrent extraneural metastatic medulloblastoma in a young adult: durable complete remission with Ewing sarcoma chemotherapy regimen and consolidation with autologous bone marrow transplantation and local radiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy; Cerebellar Neoplasms; Cycloph | 2013 |
Diagnosis and treatment of lymph node metastases in pediatric rhabdomyosarcoma in the Netherlands: a retrospective analysis.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brachytherapy; Child; Child, Pre | 2014 |
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Chlorambuc | 2014 |
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
Topics: Acute Kidney Injury; Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Antibo | 2014 |
Cutaneous Langerhans cell sarcoma relapsing systemically: Complete remission with the EPIG regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Hu | 2015 |
Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Do | 2016 |
Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparagine; Chemoradiotherapy; Cisplati | 2015 |
Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 2016 |
Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dexamethasone; | 2016 |
Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Female; Humans; Ifosfamide; Male; Middle Aged; Neop | 2009 |
Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexameth | 2009 |
Autologous stem cell transplant in a patient with Down syndrome and relapsed Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Combined Modality Ther | 2009 |
Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Ther | 2010 |
[Serious cutaneous toxicity following ifosfamide, gemcitabine and vinorelbine therapy in a patient with relapsed Hodgkin lymphoma and ichthyosis].
Topics: Deoxycytidine; Drug Eruptions; Gemcitabine; Hodgkin Disease; Humans; Ichthyosis; Ifosfamide; Male; M | 2009 |
Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dexamethasone; Etoposide; Hodgkin Disease; Hu | 2011 |
Acute pancreatitis induced by ifosfamide therapy.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Ca | 2010 |
[A case of recurrent high-grade endometrial stromal sarcoma controlled by a combination of Ifosfamide, adriamycin, and cisplatin].
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Endomet | 2010 |
Ifosfamide, carboplatin and etoposide in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2011 |
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemoth | 2011 |
Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplat | 2012 |
High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 2013 |
Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined C | 2013 |
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Centra | 2013 |
Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb | 2002 |
High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 2002 |
Recurrent atrial ectopic tachycardia following chemotherapy with ifosfamide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Electrocardiography; H | 2004 |
High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Female; Hu | 2005 |
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; F | 2005 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carm | 2005 |
IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2005 |
[MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Drug Resistance, Neo | 2005 |
[IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; | 2006 |
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Deoxycyti | 2007 |
[Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2007 |
[Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2007 |
Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults.
Topics: Adolescent; Adult; Anaphylaxis; Asparaginase; Drug Administration Schedule; Drug Therapy, Combinatio | 1981 |
IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cyclophosphamide; Drug | 1982 |
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytar | 1995 |
Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Mar | 1995 |
Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine | 1995 |
Results of treatment of small non-cleaved cell lymphoma in patients without positive HIV serology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Cyclophospha | 1993 |
Ifosfamide and etoposide in recurrent childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Eto | 1995 |
[The effect of cytostatics on the course and outcomes of experimental herpes infection in rabbits].
Topics: Acute Disease; Animals; Female; Herpesviridae; Ifosfamide; Immunosuppressive Agents; Keratitis, Herp | 1993 |
[Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; | 1994 |
Long-term disease-free survival in a child with refractory metastatic malignant germ cell tumor treated by high-dose chemotherapy with autologous bone marrow rescues.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Cisplat | 1994 |
The N-dechloroethylation of ifosfamide: using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway.
Topics: Adult; Biotransformation; Female; Humans; Ifosfamide; Infusions, Intravenous; Pelvic Neoplasms; Recu | 1996 |
Recurrent exacerbation of acne by granulocyte colony-stimulating factor administration.
Topics: Acne Vulgaris; Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic | 1996 |
Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Marrow Transplant | 1996 |
Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Ther | 1997 |
Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1997 |
High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: pattern of failure and implications for involved-field radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Etoposi | 1997 |
[High-dose chemotherapy and reinfusion of hematopoietic stem cells in advanced germ cells tumors with poor prognosis--the position in 1996].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophospha | 1997 |
Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 1998 |
Recurrent ifosfamide-induced hyponatraemia.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Cranial Nerve Neoplasms; Female; Humans; Hyponatremia | 1997 |
Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Drug Administrati | 1999 |
Unique alterations of thyroid function parameters after i.v. administration of alkylating drugs (cyclophosphamide and ifosfamide).
Topics: Adult; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexameth | 1999 |
[Neoadjuvant radiochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 1999 |
High-dose ifosfamide and etoposide infusion plus methylprednisolone for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Hodgkin Disease; Humans; I | 2000 |
[Pigmented villonodular synovitis: apropos of 3 cases].
Topics: Adult; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Arthroplasty, Replaceme | 2001 |
[Subcutaneous inflammatory edema induced by MINE chemotherapy].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capillary Leak Syndrome; Creatin | 2001 |
Prolonged second response to cisplatin, etoposide, and ifosfamide in a child with a recurrent brainstem glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Cisplatin; Etoposide; F | 2001 |
The role of ifosfamide in cytoreduction, stem cell mobilization and high-dose therapy in relapsed/refractory malignant lymphomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Ste | 2001 |
Expression of P53 and bcl-2 proteins in T-cell lymphoblastic lymphoma: prognostic implications.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclopho | 2002 |
[Ifosfamide in the treatment of nephrotic syndrome (author's transl)].
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Ifosfamide; Infant; Male; Nep | 1977 |
Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 1992 |
No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology.
Topics: Bone Neoplasms; Child; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Ifosfamide; Mal | 1992 |
Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Ad | 1991 |
Squamous cell carcinoma antigen and carcinoembryonic antigen levels as prognostic factors for the response of cervical carcinoma to chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; | 1990 |
Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Follow-Up Studies; H | 1990 |
Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evaluati | 1989 |
A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Ifosfamide; | 1986 |
Ifosfamide and etoposide as salvage therapy for non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Ifosfamide; Lymphoma; Methotrexat | 1986 |